Antiparkinsonism Drugs: Pharmacology, Dosing and Safe Management of Parkinson Disease
On this page
1 Overview
Parkinson disease (PD) is a progressive neurodegenerative disorder of dopaminergic neurons in the substantia nigra pars compacta with intraneuronal α-synuclein (Lewy body) accumulation. Its pharmacology is rational and therefore memorable: restore striatal dopamine, or rebalance the dopamine–acetylcholine imbalance its loss creates. No drug slows the disease — all treatment is symptomatic — so therapy is a lifelong exercise in matching drugs to function, age and side-effect tolerance. All antiparkinsonian drugs are symptomatic; levodopa is the most effective and the reference against which others are measured.
2 Learning Objectives
- Explain why levodopa (not dopamine) is given, and why carbidopa is combined with it.
- Compare the mechanism, uses and adverse effects of dopamine agonists, MAO-B inhibitors, COMT inhibitors, amantadine and anticholinergics.
- Describe wearing-off, dyskinesias and the "on-off" phenomenon, and their management.
- Apply safe prescribing principles: never stop levodopa abruptly, titrate slowly, watch for impulse-control disorders and psychosis.
- Recognise drug-induced parkinsonism and its management.
3 Pathophysiology Rationale for Drug Action
The nigrostriatal pathway normally delivers dopamine to the striatum to facilitate movement. When ~60–80% of substantia nigra neurons are lost, striatal dopamine falls and the direct (movement-facilitating) pathway is under-driven while the indirect pathway is over-active — producing the cardinal features: bradykinesia (obligatory), resting tremor, rigidity and postural instability. Two pharmacological corollaries follow: (1) replacing or mimicking dopamine treats bradykinesia and rigidity best (tremor responds least); (2) with dopamine low, the cholinergic system is relatively over-active, so anticholinergics help mainly tremor and rigidity — and are hazardous in the elderly, whose cholinergic reserve is already low.
4 Levodopa & Carbidopa — the Gold Standard
- Why levodopa — dopamine itself cannot cross the blood–brain barrier; its amino-acid precursor levodopa crosses via the LAT1 transporter and is decarboxylated to dopamine in surviving neurons and glia.
- Why carbidopa — peripheral dopa-decarboxylase converts most levodopa to dopamine before it reaches the brain, causing nausea, vomiting, tachycardia and hypotension. Carbidopa blocks this conversion peripherally (it does not cross the BBB), increasing CNS delivery 4–5-fold and abolishing most peripheral effects. Benserazide does the same in other markets.
- Dosing — start low, e.g. carbidopa/levodopa 25/100 mg half to one tablet 2–3 times daily; titrate to effect. Modified-release forms smooth "wearing off"; intestinal gel and rotigotine patch exist for advanced disease.
- Adverse effects — early: nausea, hypotension, somnolence (including sudden sleep attacks). Later: motor fluctuations and dyskinesias (see below); psychiatric effects — hallucinations, impulse-control problems, psychosis at higher doses.
- Critical safety rule — never stop levodopa abruptly: sudden withdrawal can precipitate a parkinsonism-hyperpyrexia (neuroleptic malignant–like) syndrome with rigidity, fever, autonomic instability and rhabdomyolysis. If it must stop (e.g. severe psychosis), taper and substitute another agent.
5 Other Drug Classes
Dopamine receptor agonists
Pramipexole, ropinirole, rotigotine (non-ergot) and bromocriptine, cabergoline (ergot) stimulate striatal D2/D3 receptors directly. Used as monotherapy in younger patients to delay levodopa and its dyskinesias, and as add-on later. Key adverse effects: nausea, orthostatic hypotension, sudden sleep attacks, and — uniquely important — impulse-control disorders (pathological gambling, hypersexuality, binge eating, compulsive shopping) and leg oedema. Ergot agents carry fibrotic (valvular heart, pleuropulmonary) risks — rarely used now. Rotigotine patch suits non-adherent patients; apomorphine injection rescues "off" episodes in advanced disease.
MAO-B inhibitors
Selegiline, rasagiline (and safinamide) selectively inhibit monoamine oxidase B, reducing dopamine catabolism in the striatum. Mild benefit as early monotherapy or levodopa adjunct. Selegiline is given in the morning (insomnia at higher doses); avoid >10 mg/day, where MAO-A inhibition begins and tyramine ("cheese effect") hypertensive crisis becomes possible. Rasagiline 0.5–1 mg daily is once-daily and metabolically simpler.
COMT inhibitors
Entacapone (200 mg with each levodopa dose, max 8×/day) blocks peripheral catechol-O-methyltransferase, prolonging levodopa's action — a wearing-off adjunct only, with no effect alone (it does not cross the BBB meaningfully). Adverse effects mirror levodopa excess (dyskinesia, hallucinations) plus orange discoloration of urine. Tolcapone acts centrally but carries hepatotoxicity — monitor LFTs or avoid. Avoid combining entacapone with tolcapone.
Amantadine
An old antiviral with NMDA-antagonist and anticholinergic actions; increases dopamine release and blocks reuptake. Best uses: early mild disease and — most usefully today — levodopa-induced dyskinesias (100 mg 2–3×/day). Caution in renal impairment (renally cleared). Adverse effects: livedo reticularis, pedal oedema, confusion, hallucinations, QT prolongation.
Anticholinergics
Trihexyphenidyl (benzhexol), benztropine, orphenadrine block muscarinic receptors, rebalancing dopamine–acetylcholine. They help tremor and rigidity, not bradykinesia, and are the drugs for drug-induced parkinsonism when the causative dopamine blocker (e.g. haloperidol, metoclopramide) must continue. Adverse effects are the anticholinergic burden: confusion, hallucinations, urinary retention, constipation, tachycardia, blurred vision, dry mouth — avoid in the elderly, glaucoma and prostatism.
6 Drug Monographs: Doses, Indications & Safety
Each antiparkinsonian drug as a full monograph: mechanism → indications → adult dose → paediatric dose → adverse effects → contraindications → interactions → patient advice. Doses are standard teaching doses — confirm against the current Uganda Clinical Guidelines before prescribing.
Levodopa/carbidopa (gold standard)
Scroll the table sideways on a smaller screen.
| Levodopa + carbidopa — dopamine precursor + peripheral decarboxylase inhibitor | |
|---|---|
| Mechanism | Levodopa crosses the blood–brain barrier (LAT1 transporter) and is converted to dopamine in the striatum; carbidopa blocks peripheral dopa-decarboxylase so more reaches the brain with fewer peripheral effects |
| Indications | Parkinson disease — most effective drug for all motor features (bradykinesia and rigidity respond best); all stages and ages |
| Adult dose | Start carbidopa/levodopa 25/100 mg half–one tablet 2–3 times daily with food; titrate weekly to effect (usual 1 tablet 3–4 times daily); controlled-release for wearing-off |
| Paediatric dose | Not applicable (rare dopamine-responsive dystonia uses are specialist) |
| Adverse effects | Early: nausea, postural hypotension, somnolence/sudden sleep attacks. Late (years): wearing-off, dyskinesias, on-off phenomenon; hallucinations, impulse-control problems, psychosis |
| Contraindications | Psychosis, narrow-angle glaucoma (caution), melanoma (historical caution), MAO-A inhibitors (stop ≥14 days) |
| Interactions | Antiemetics that block D2 (metoclopramide, prochlorperazine) and antipsychotics antagonise its effect — use domperidone/ondansetron instead; non-selective MAOIs (hypertensive crisis); iron and high-protein meals reduce absorption |
| Patient advice / monitoring | Never stop abruptly — risk of parkinsonism-hyperpyrexia; take with low-protein meals; report hallucinations, sleep episodes and gambling/impulse changes; standing slowly (postural hypotension) |
Pramipexole (dopamine D2/D3 agonist)
Scroll the table sideways on a smaller screen.
| Pramipexole — non-ergot dopamine receptor agonist | |
|---|---|
| Mechanism | Direct D2/D3 receptor stimulation (preferential D3 activity — links to its impulse-control effects) |
| Indications | Early Parkinson monotherapy (younger patients) to delay levodopa; adjunct to levodopa; restless legs syndrome |
| Adult dose | Start 0.125 mg 3 times daily; increase weekly by 0.125–0.25 mg/dose; usual 0.5–1.5 mg/day (IR); extended-release start 0.375 mg once daily |
| Paediatric dose | Not established |
| Adverse effects | Nausea, orthostatic hypotension (first-dose), somnolence/sudden sleep attacks, leg oedema, dyskinesia as adjunct; impulse-control disorders (gambling, hypersexuality, binge eating) |
| Contraindications | Psychosis; caution in elderly (cognitive sensitivity), renal impairment (dose-adjust) |
| Interactions | Dopamine antagonists (antipsychotics, metoclopramide) reduce effect; CYP interactions are minor (renally cleared — cimetidine, amantadine raise levels) |
| Patient advice / monitoring | Take the first dose at night, rise slowly; ask specifically about gambling, spending, sexual urges — patients rarely volunteer this; no driving if sleep attacks occur; renal dose review |
Ropinirole (dopamine D2/D3 agonist)
Scroll the table sideways on a smaller screen.
| Ropinirole — non-ergot dopamine receptor agonist | |
|---|---|
| Mechanism | Direct D2/D3 receptor stimulation |
| Indications | Early Parkinson monotherapy or levodopa adjunct; restless legs syndrome |
| Adult dose | Start 0.25 mg 3 times daily; increase weekly (0.25 → 1 → 2 → 3 mg/dose); usual 9–16 mg/day |
| Paediatric dose | Not established |
| Adverse effects | Nausea, somnolence/sleep attacks, orthostatic hypotension, leg oedema, impulse-control disorders, dyskinesia as adjunct |
| Contraindications | As pramipexole; caution in elderly |
| Interactions | CYP1A2 inhibitors (ciprofloxacin, fluvoxamine) raise levels; smokers (tobacco induces CYP1A2) may need more; dopamine antagonists oppose effect |
| Patient advice / monitoring | Same vigilance as pramipexole for impulse control and sleep attacks; take with food to reduce nausea |
Rotigotine (transdermal dopamine agonist)
Scroll the table sideways on a smaller screen.
| Rotigotine — D2/D3 agonist, once-daily patch | |
|---|---|
| Mechanism | Direct D2/D3 receptor stimulation delivered continuously through the skin — smooth, stable levels without peak-related dyskinesia |
| Indications | Early and advanced Parkinson disease; patients with swallowing difficulty or adherence problems; restless legs syndrome (lower doses); perioperative levodopa substitution |
| Adult dose | Start 2 mg/24 h patch, increase weekly; usual 4–8 mg/24 h; RLS: 1–3 mg/24 h |
| Paediatric dose | Not established |
| Adverse effects | Application-site skin reactions, nausea, somnolence, hypotension, impulse-control disorders, hallucinations |
| Contraindications | As other agonists; avoid in psychosis |
| Interactions | Few CYP interactions (hepatic); dopamine antagonists oppose effect; heat increases absorption (sauna, fever) |
| Patient advice / monitoring | Apply at the same time daily to rotating sites; remove old patch; wash hands after; report skin reactions and impulse-control changes |
Selegiline (MAO-B inhibitor)
Scroll the table sideways on a smaller screen.
| Selegiline — selective monoamine oxidase B inhibitor | |
|---|---|
| Mechanism | Selectively inhibits MAO-B → slows striatal dopamine breakdown; at >10 mg/day loses selectivity (tyramine risk begins) |
| Indications | Early Parkinson monotherapy (mild benefit); adjunct to levodopa for wearing-off |
| Adult dose | 5 mg twice daily (morning + midday) or 10 mg morning; avoid doses >10 mg/day; take in the morning to avoid insomnia |
| Paediatric dose | Not established |
| Adverse effects | Nausea, insomnia, dizziness, orthostatic hypotension; hallucinations, dyskinesia as adjunct; high doses: tyramine hypertensive crisis |
| Contraindications | Pheochromocytoma; caution with other serotonergic drugs (syndrome risk is low at selective doses) |
| Interactions | Meperidine/pethidine (serotonin syndrome — avoid); SSRIs/SNRIs (theoretical serotonin risk — use caution); carbamazepine, phenytoin, rifampicin lower levels |
| Patient advice / monitoring | Morning dosing; avoid tyramine-heavy diets at higher doses; report insomnia, vivid dreams, hallucinations |
Rasagiline (MAO-B inhibitor)
Scroll the table sideways on a smaller screen.
| Rasagiline — selective MAO-B inhibitor | |
|---|---|
| Mechanism | Irreversible, selective MAO-B inhibition → prolonged striatal dopamine availability |
| Indications | Early Parkinson monotherapy; adjunct to levodopa |
| Adult dose | 1 mg once daily (0.5 mg with moderate hepatic impairment or ciprofloxacin) |
| Paediatric dose | Not established |
| Adverse effects | Headache, nausea, postural hypotension, insomnia; dyskinesia and hallucinations as levodopa adjunct |
| Contraindications | Pheochromocytoma; hepatic impairment (avoid or halve) |
| Interactions | Sympathomimetics, SSRIs/SNRIs (serotonin syndrome — caution, especially with mirtazapine or dextromethorphan-containing products); CYP1A2 inhibitors (ciprofloxacin) raise levels |
| Patient advice / monitoring | Once daily, any time but keep consistent; avoid pseudoephedrine-containing cold remedies; report headache or BP rise |
Entacapone (COMT inhibitor)
Scroll the table sideways on a smaller screen.
| Entacapone — peripheral catechol-O-methyltransferase inhibitor | |
|---|---|
| Mechanism | Blocks peripheral COMT → prolongs levodopa's plasma half-life and smooths its CNS delivery; no effect alone |
| Indications | Adjunct to levodopa for wearing-off (end-of-dose deterioration) |
| Adult dose | 200 mg with each levodopa dose (max 8 doses/day); dose reduction may be needed once dyskinesia appears |
| Paediatric dose | Not established |
| Adverse effects | Dyskinesia, hallucinations, nausea, diarrhoea, orange discoloration of urine (harmless), abdominal pain |
| Contraindications | Hepatic impairment (avoid — tolcapone alternative is worse); do not combine with tolcapone |
| Interactions | Enhances all levodopa effects (incl. toxicity); do not combine with non-selective MAOIs; iron salts chelate it (space doses) |
| Patient advice / monitoring | Only works alongside levodopa; orange urine is expected; report new or worse dyskinesia/hallucinations promptly — dose may need reduction |
Amantadine (NMDA antagonist)
Scroll the table sideways on a smaller screen.
| Amantadine — NMDA antagonist, anticholinergic, ↑ dopamine release | |
|---|---|
| Mechanism | Multiple: NMDA-receptor antagonism (antidyskinetic effect), increases dopamine release and blocks its reuptake, anticholinergic activity |
| Indications | Early mild Parkinson disease; levodopa-induced dyskinesias (its most useful modern role); historically influenza A prophylaxis |
| Adult dose | 100 mg once–twice daily, usual 100 mg 2–3 times daily (max 400 mg/day) |
| Paediatric dose | Not for Parkinson disease; influenza dosing is historical |
| Adverse effects | Livedo reticularis (harmless mottling), pedal oedema, confusion, hallucinations, insomnia, QT prolongation, seizures |
| Contraindications | Severe renal impairment (renally cleared — reduce dose if eGFR low), psychosis, seizure disorders (caution) |
| Interactions | Anticholinergics compound its effects; diuretics (hydrochlorothiazide/triamterene) raise levels; alcohol worsens CNS effects |
| Patient advice / monitoring | Early in the day (insomnia); report mottled skin (harmless), ankle swelling, confusion; renal function review; do not stop flu-like after long use without advice |
Trihexyphenidyl (benzhexol, anticholinergic)
Scroll the table sideways on a smaller screen.
| Trihexyphenidyl — centrally acting muscarinic antagonist | |
|---|---|
| Mechanism | Blocks central muscarinic receptors — rebalances the dopamine–acetylcholine ratio in the striatum |
| Indications | Tremor-predominant Parkinson disease (younger patients); drug-induced parkinsonism/extrapyramidal symptoms when the causative drug must continue; useful adjunct to haloperidol in psychosis care |
| Adult dose | Start 1 mg once daily; increase by 2 mg every 3–5 days; usual 6–10 mg/day in divided doses (max 20 mg/day) |
| Paediatric dose | >3 years (drug-induced EPS): 1–2 mg twice daily, specialist use |
| Adverse effects | Confusion and hallucinations, memory impairment, urinary retention, constipation, tachycardia, blurred vision, dry mouth, heat intolerance |
| Contraindications | Avoid in the elderly, narrow-angle glaucoma, prostatism/urinary retention, tardive dyskinesia (worsens it), cognitive impairment |
| Interactions | Additive anticholinergics (antihistamines, TCAs, antipsychotics) → delirium risk; reduces levodopa absorption; antagonises metoclopramide |
| Patient advice / monitoring | Expect dry mouth (sips of water, sugar-free gum); avoid in hot weather/dehydration (heat stroke risk); report retention, confusion, palpitations |
7 Master Comparison Table
Scroll the table sideways on a smaller screen.
| Class / drug | Mechanism | Best use | Signature adverse effects |
|---|---|---|---|
| Levodopa + carbidopa | Dopamine precursor + peripheral decarboxylase inhibitor | Gold standard; bradykinesia, all stages | Wearing-off, dyskinesia, nausea, hypotension, hallucinations; never stop abruptly |
| Dopamine agonists (pramipexole, ropinirole, rotigotine) | D2/D3 receptor stimulation | Younger patients; early monotherapy; RLS; adjunct | Impulse-control disorders, sleep attacks, hypotension, leg oedema |
| MAO-B inhibitors (selegiline, rasagiline) | ↓ Dopamine breakdown (B) | Early disease; wearing-off adjunct | Nausea, insomnia; tyramine risk at high selegiline dose |
| COMT inhibitors (entacapone) | ↓ Peripheral levodopa metabolism | Wearing-off adjunct only | Dyskinesia, hallucinations, orange urine; tolcapone: hepatotoxic |
| Amantadine | NMDA antagonist; ↑ dopamine release | Mild disease; dyskinesias | Livedo reticularis, oedema, confusion, renal caution |
| Anticholinergics (trihexyphenidyl, benztropine) | Muscarinic blockade | Tremor; drug-induced parkinsonism | Confusion, retention, tachycardia — avoid in elderly |
8 Motor Fluctuations & Long-Term Complications
- Wearing-off (end-of-dose) — predictable return of symptoms before the next dose as disease shortens levodopa's effect. Manage by fractionating doses, adding entacapone, using controlled-release formulations, or adding a dopamine agonist/MAO-B inhibitor.
- On-off phenomenon — unpredictable, sudden switches between mobility ("on", often with dyskinesia) and immobility ("off"), unrelated to dosing times. Harder to treat: adjust administration, add apomorphine or consider deep brain stimulation (subthalamic nucleus).
- Levodopa-induced dyskinesias — peak-dose choreiform movements after years of therapy, worse in young-onset patients. Reduce individual doses, add amantadine, or consider surgery.
- Freezing — sudden, transient inability to move, often at doorways; responds poorly to drugs — visual cueing and physiotherapy help.
9 Prescribing Principles & Patient Safety
- Start low, go slow — titrate to the minimum dose that restores function, not to abolish every symptom.
- Individualise by age — younger patients start with agonists or MAO-B inhibitors to delay levodopa dyskinesia; older patients start levodopa (cognitive tolerance of agonists is poor).
- Never stop abruptly — risk of parkinsonism-hyperpyrexia; taper and substitute.
- Screen and counsel — warn about sleep attacks (driving), orthostatic hypotension (first-dose effect with agonists), impulse-control disorders (ask specifically), hallucinations and psychosis (dose reduction; quetiapine or clozapine if an antipsychotic is unavoidable — avoid D2 blockers).
- Non-motor symptoms matter — constipation, depression, rapid eye movement sleep behaviour disorder, autonomic dysfunction; treat the patient, not the scan.
10 Special Situations
- Drug-induced parkinsonism — D2 blockers: first-generation antipsychotics (haloperidol, fluphenazine), metoclopramide, prochlorperazine, reserpine, tetrabenazine. Stop the culprit; if it must continue (psychosis), switch to low-D2 agents (quetiapine, clozapine) and treat with anticholinergics or amantadine. Domperidone is preferred as an antiemetic in PD because it does not cross the BBB.
- Perioperative care — continue levodopa through nil-by-mouth periods (NG or transdermal rotigotine); abrupt omission precipitates crisis.
- Psychosis in PD — reduce Parkinson drugs in reverse order of potency (anticholinergic → agonist → MAO-B/COMT → levodopa); if an antipsychotic is essential, use quetiapine or clozapine (minimal D2 blockade).
- Advanced options — deep brain stimulation, levodopa-carbidopa intestinal gel, apomorphine infusion for refractory fluctuations.
11 Viva & Exam Points
- Gold standard — levodopa + carbidopa; bradykinesia/rigidity respond best, tremor least.
- Carbidopa — peripheral decarboxylase inhibitor; does not cross BBB.
- Agonists — impulse-control disorders; young patients; rotigotine patch.
- Entacapone — COMT inhibitor, wearing-off adjunct; orange urine. Tolcapone — hepatotoxic.
- Selegiline — MAO-B; morning dosing; avoid >10 mg (tyramine crisis).
- Amantadine — dyskinesias; livedo reticularis; renal caution.
- Anticholinergics — tremor and drug-induced parkinsonism; avoid elderly.
- Never stop levodopa abruptly — parkinsonism-hyperpyrexia.
12 References
- Parkinson Disease. StatPearls. NCBI Bookshelf — motor symptom pharmacotherapy, carbidopa rationale.
- Parkinsonism. StatPearls. NCBI Bookshelf — drug classes, dosing, drug-induced parkinsonism.
- Dopamine Agonists. StatPearls. NCBI Bookshelf — mechanisms, impulse-control adverse effects, rotigotine, apomorphine.
- Levodopa (L-Dopa). StatPearls. NCBI Bookshelf — mechanism, indications.
- Carbidopa. StatPearls. NCBI Bookshelf — combination rationale, adverse effects, wearing-off.
For education only. Apply current Uganda Clinical Guidelines and local protocols when managing patients.